Taysha Gene Therapies, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

TSHA

organization

SIC: 2836

SEC Insider

$37.4M

185 transactions

Summary

Taysha Gene Therapies, Inc. (TSHA) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $27.0MSales: $9.5M11 insiders

Date	Insider	Type	Value
2026-04-10	Nagendran Sukumar(President and Head of R&D)	Sell	$892K
2026-01-23	Nolan Sean P.(Chief Executive Officer)	Sell	$650K
2026-01-23	Nagendran Sukumar(President and Head of R&D)	Sell	$423K
2026-01-23	Alam Kamran(CHIEF FINANCIAL OFFICER)	Sell	$375K
2026-01-26	Nolan Sean P.(Chief Executive Officer)	Sell	$190K
2026-01-26	Nagendran Sukumar(President and Head of R&D)	Sell	$124K
2026-01-26	Alam Kamran(CHIEF FINANCIAL OFFICER)	Sell	$110K
2026-04-10	Nagendran Sukumar(President and Head of R&D)	M	$33K
2026-02-04	Alam Kamran(CHIEF FINANCIAL OFFICER)	Sell	$7K
2026-06-01	Donenberg Phillip B.	A	$0
2026-06-01	Donenberg Phillip B.	A	$0
2026-06-01	Stalfort John A III	A	$0
2026-06-01	Stalfort John A III	A	$0
2026-06-01	Sepp-Lorenzino Laura	A	$0
2026-06-01	Sepp-Lorenzino Laura	A	$0
2026-06-01	Long Alison S	A	$0
2026-06-01	Long Alison S	A	$0
2026-04-10	Nagendran Sukumar(President and Head of R&D)	M	$0
2026-01-12	Nolan Sean P.(Chief Executive Officer)	A	$0
2026-01-12	Nolan Sean P.(Chief Executive Officer)	A	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Taysha Gene Therapies, Inc. — Contributions, Lobbying & Contracts | Poliscope